LH LABCORP HOLDINGS INC. Insider Trading

CEO Adam H Schechter sold 5,903 shares of LH at $254.50 on 2026-05-11 under pre-arranged 10b5-1 plan; holds 107,234 shares post-sale.

Adam H Schechter, President & CEO, executed a scheduled sale of 5,903 shares at $254.50 on 2026-05-11 under a pre-arranged 10b5-1 trading plan, reducing his holdings from 113,137 shares to 107,234 shares. This is the sixth consecutive sale at LH, with prior same-ticker trades showing mixed short-term outcomes: 30-day returns ranging from -7.2% to +4.5%, and 90-day returns from -9.5% to +6.9%. The current stock price of $266.16 is -9.4% from the 52-week high, though up +4.6% over the past 30 days. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it reflects a pre-committed execution strategy rather than a market timing decision. The pattern of regular sales warrants tracking against quarterly fundamentals and broader market movement to assess whether systematic reductions signal changing conviction or represent a predetermined portfolio adjustment plan.

Schechter (CEO) sells 8,705 LH shares at $279.96; holds 80,773 post-transaction

Adam H. Schechter, President & CEO, sold 8,705 shares of LabCorp at $279.96 on 2026-03-03 for a total value of $2,437,047.45. Post-transaction, he retains 80,773 shares, representing a -9.7% reduction in his disclosed holdings. Schechter's historical performance selling at LabCorp is mixed: across his 5 prior trades at LH, only 1 of 4 measurable sales showed a 90-day positive outcome (well-timed by the standard that negative post-sale returns indicate foresight of decline). The transaction occurs when LH stock is at $275.92, down -5.2% from the 52-week high of $290.93, while the company's fundamentals remain solid (quarterly revenue of $3,563,500,000.00, net income of $261,100,000.00, and annual revenue growth of +7.2%), yielding a P/E of 23.07. This sale is routine portfolio activity and does not suggest a material shift in CEO conviction.

CEO Adam Schechter sold 5,273 shares of LH at $284.38 on 2026-02-11 for $1,499,535.74 (1.5M)

Adam H. Schechter, President & CEO, sold 5,273 shares at $284.38, reducing holdings by 5.6% from 94,751 to 89,478 shares. This is his 6th open-market sale across all tickers; however, his prior trades at LabCorp show mixed timing—only 1 of 5 prior LH sales occurred before subsequent 90-day gains, suggesting inconsistent entry/exit discipline specific to this issuer. The stock currently trades at $282.63, down 2.8% from its 52-week high of $290.93, while the broader 30-day trend is positive at +7.9%, indicating the sale occurred near cyclical strength rather than weakness. LabCorp's fundamentals remain solid with $3.6B quarterly revenue, +7.0% annual growth, and a 27.39 P/E, leaving no obvious valuation distress as a catalyst for the transaction.

CEO Schechter sells 5,745 LH shares at $262.75; holds 87,574 post-sale (-6.2% reduction)

Schechter Adam H, President & CEO of LabCorp, sold 5,745 shares on 2025-11-11 for $262.75 per share, reducing his holdings by 6.2% to 87,574 shares. The transaction occurred near the 52-week trading range but 7.9% below the high. At this same ticker, his prior four sales generated mixed 90-day outcomes: one well-timed (negative return), three poorly timed (positive returns), suggesting a 25% hit rate on timing at LH specifically. The company's fundamentals remain solid with $3.6B in quarterly revenue, +7.0% annual growth, and a P/E of 25.96, providing no obvious distress signal. The sale appears routine in size and does not materially signal material concern about the business.

Director Parham Richelle P sold 7,009 shares of LH at $254.28, reducing holdings by 74.0% to 2,469 shares.

Director Parham Richelle P executed a substantial sale of 7,009 shares at $254.28 on 2025-10-31, valued at $1,782,273.05, reducing her shareholding from 9,478 shares to 2,469 shares—a 74.0% reduction in her position. The transaction occurred as the stock is trading at $252.33, down 13.3% from its 52-week high of $290.93 and down 8.9% over the prior 30 days, suggesting the sale occurred amid recent price weakness. LH trades at a P/E of 24.45 with strong fundamentals: $3.6B in latest quarterly revenue, $261.1M in net income, and 7.0% annual revenue growth, indicating the company's underlying performance does not obviously justify the recent downward pressure. The large reduction in her direct stake raises a question about director confidence in near-term prospects, particularly given the magnitude of the decrease relative to her retained holdings.

EVP/CLO van der Vaart sells 3,903 shares of LH at $271.42 (total value $1,059,371.38), reducing stake by -63.2% to 2,273 shares post-transaction

Sandra D van der Vaart, EVP and Chief Legal Officer of LabCorp, sold 3,903 shares on 2025-08-13 for $1,059,371.38, eliminating nearly two-thirds of her prior holding (6,176 shares down to 2,273 shares). The sale occurred near the 52-week high (-0.8%), and her prior sell at this ticker on 2024-03-28 exhibited well-timed exit pricing (stock fell 6.2% over 90 days after that trade). Her cross-ticker track record shows 100.00% well-timed rate across prior sells, though her single same-ticker history provides a consistent signal. The substantial reduction in her equity exposure—a $1.1M transaction at a near-peak price—combined with her track record of well-timed exits, merits monitoring of whether this signals a broader view on the company's outlook relative to current valuations.

CEO Schechter sells 5,643 LH shares at $266.78; holdings down to 93,319 shares post-sale

Schechter Adam H (President & CEO) sold 5,643 shares of LABCORP HOLDINGS INC. (LH) at $266.78 on 2025-08-11, reducing his holdings by 5.7% to 93,319 shares. The sale occurred near the 52-week high of $272.54, with LH trading at +9.1% over 30 days and +10.7% over 90 days at time of filing. Schechter's three prior sales at LH all generated positive 90-day returns (ranging +1.2% to +6.9%), meaning none were well-timed by the insider's own historical pattern; this sale's timing relative to subsequent price action remains to be observed. The company shows solid fundamentals with $3.5B quarterly revenue, +7.0% annual growth, and a P/E of 29.66, though the stock's recent momentum and proximity to 52-week highs provides context for the CEO's liquidation decision.

LH CEO Adam Schechter sold 6,105 shares at $248.73 (May 12); retains 98,962 shares. Stock up 12.9% in 30 days.

Schechter sold 6,105 shares for $1,518,496.65, reducing his position by 5.8% but maintaining substantial holdings of 98,962 shares. His prior two sales at LH produced negative 90-day returns of -3.7% and -5.7%, yet both trades ended with positive cumulative gains (+2.6% and +1.2% respectively), suggesting weak timing on exit points. The current sale occurred near the 52-week high (only 2.6% below the $256.81 peak), and LH stock has appreciated 12.9% over the prior 30 days and 3.7% over 90 days, indicating the CEO executed this sale into recent strength. With a P/E of 28.64 and annual revenue growth of 7.0%, the company trades at a premium valuation; the sale reflects portfolio adjustment rather than a signal tied to operational concerns.

Mark S. Schroeder (EVP, Pres Diagnostics & COO) sold 2,635 shares of LH at $231.67; stock down 7.3% in 30 days post-sale.

Schroeder sold 2,635 shares (34.7% of his pre-transaction holding of 7,595 shares) at $231.67 on 2025-03-28, reducing his position from 7.6K to 5.0K shares. The stock has declined 7.3% over the subsequent 30 days and trades 9.4% below its 52-week high of $256.81. His same-ticker trade history at LH shows 3 prior measurable 90-day outcomes, all negative: −13.8%, −9.4%, and −6.3%, consistent with a pattern of well-timed exit execution. His cross-ticker track record shows 4 prior sells with an average 90-day return of −8.1% and a 100.00% well-timed rate, indicating his open-market sales have historically preceded declines. The company's fundamentals remain solid (7.0% annual revenue growth, P/E 25.52, $3.3B quarterly revenue), but the consistent post-sale price weakness in this insider's history warrants attention as a potential technical or fundamental headwind signal.

EVP Mark Schroeder sold 5,339 shares of LH at $249.23 (-51.8% of holdings); all 3 prior LH sales were well-timed at 90-day mark

Mark Schroeder, Executive Vice President and President of Diagnostics & COO at LabCorp, sold 5,339 shares at $249.23 on 2025-02-28, reducing his holdings from 10,299 to 4,960 shares. This represents a -51.8% reduction in his position, a material reduction in ownership stake. Schroeder has a demonstrated track record at this specific ticker: his 3 prior open-market sales at LH were all well-timed, with negative 90-day returns ranging from -6.3% to -9.4%, meaning the stock declined after each sale. His cross-ticker track record shows a 100.00% well-timed rate on sells with an average 90-day return of -8.1%, indicating consistent discipline in timing exits. The stock is currently trading at $256.81, near the 52-week high of $256.81, suggesting this sale occurred during a period of elevated valuation relative to recent price action.